Supernus Reaches Key Milestone Toward Proposed Merger with Indivior Following Shareholder Approval

Vote clears critical threshold in establishing Supernus, Inc. as a scaled, diversified CNS biopharmaceutical leader

Supernus Pharmaceuticals, Inc. welcomed the decisive backing of shareholders today, who formally voted to approve the pending all-stock merger of equals.

This vote marks an important milestone toward completing the merger announced in August 2026, with closing anticipated on November 2, 2026, subject to customary closing conditions. Following closing, the combined organization will officially commence operations as Supernus, Inc., trading on the Nasdaq Global Market under the ticker symbol "SUPN."

Once complete, the merger will unite two organizations with a shared dedication to neuroscience, establishing a scaled commercial platform spanning addiction, psychiatry, and neurology. Together, the combined company will possess the expanded capabilities, financial strength, and pipeline capacity to make a meaningful difference for people living with conditions such as opioid use disorder, ADHD, Parkinson's disease, and postpartum depression, while delivering sustained, long-term value for shareholders.

Supernus Pharmaceuticals Contacts

Investors	Peter Vozzo	ICR Healthcare	+1 443 213 0505 peter.vozzo@icrhealthcare.com
Media	Diana Torres-Bixby	Burson Global	+1 917 686 0517 Diana.torres-bixby@bursonglobal.com